Pathogenesis of Inflammatory Bowel Disease and Recent Advances in Biologic Therapies

키워드

참고문헌 (142)

1. Schulenburg, H., "Evolution of the innate immune system: the worm perspective", Immunol. Rev, 198, pp.36~58 (2004)
2. Maloy, K. J., "Intestinal homeostasis and its breakdown in inflammatory bowel disease", Nature, 474, pp.298~306 (2011)
3. Cader, M. Z., "Recent advances in inflammatory bowel disease : mucosal immune cells in intestinal inflammation", Gut, 62, pp.1653~1664 (2013)
4. Podolsky, D. K., "Inflammatory bowel disease", N. Engl. J. Med, 325, pp.928~937 (1991)
5. Abraham, C., "Inflammatory bowel disease", N. Engl. J. Med, 361, pp.2066~2078 (2009)
6. Cheon, J. H., "Genetics of inflammatory bowel diseases:a comparison between Western and Eastern perspectives", J. Gastroenterol. Hepatol, 28, pp.220~226 (2013)
7. Papadakis, K. A., "Role of cytokines in the pathogenesis of inflammatory bowel disease", Annu. Rev. Med, 51, pp.289~298 (2000)
8. Jae Hee Cheon, "Understanding the complications of anti-tumor necrosis factor therapy in East Asian patients with inflammatory bowel disease", Journal of Gastroenterology and Hepatology, 32(4), pp.769~777 (2017), Wiley-Blackwell[DOI]
9. 김원호, "Efficacy and Safety of Infliximab Therapy and Predictors of Response in Korean Patients with Crohn’s Disease: A Nationwide, Multicenter Study", Yonsei Medical Journal, 57(6), pp.1376~1385 (2016), 연세대학교의과대학[DOI]
10. van der Flier, L. G., "Stem cells, selfrenewal, and differentiation in the intestinal epithelium", Annu. Rev. Physiol, 71, pp.241~260 (2009)
11. Geremia, A., "Innate and adaptive immunity in inflammatory bowel disease", Autoimmun. Rev, 13, pp.3~10 (2014)
12. Van der, S. M., "Muc2-deficient mice spontaneously develop colitis, indicating that MUC2 is critical for colonic protection", Gastroenterology, 131, pp.117~129 (2006)
13. Heazlewood, C. K., "Aberrant mucin assembly in mice causes endoplasmic reticulum stress and spontaneous inflammation resembling ulcerative colitis", PLoS Med, 5, pp.e54~ (2008)
14. Jass, J. R., "Altered mucin expression in the gastrointestinal tract: a review", J. Cell. Mol. Med, 5, pp.327~351 (2001)
15. Kaser, A., "Inflammatory bowel disease", Annu. Rev. Immunol, 28, pp.573~621 (2010)
16. Kaser, A., "Endoplasmic reticulum stress and intestinal inflammation", Mucosal Immunol, 3, pp.11~16 (2010)
17. Cao, S. S., "The unfolded protein response and chemical chaperones reduce protein misfolding and colitis in mice", Gastroenterology, 144, pp.989~1000 (2013)
18. Wallace, K. L., "Immunopathology of inflammatory bowel disease", World J. Gastroenterol, 20, pp.6~21 (2014)
19. Peltekova, V. D., "Functional variants of OCTN cation transporter genes are associated with Crohn disease", Nat. Genet, 36, pp.471~475 (2004)
20. Park, H. J., "Identification of OCTN2 variants and their association with phenotypes of Crohn's disease in a Korean population", Sci. Rep, 6, pp.22887~ (2016)
21. Slack, E., "Innate and adaptive immunity cooperate flexibly to maintain host-microbiota mutualism", Science, 325, pp.617~620 (2009)
22. Sartor, R. B., "Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis", Nat. Clin. Pract. Gastroenterol. Hepatol, 3, pp.390~407 (2006)
23. Hermiston, M. L., "Inflammatory bowel disease and adenomas in mice expressing a dominant negative N-cadherin", Science, 270, pp.1203~1207 (1995)
24. Natividad, J. M., "Commensal and probiotic bacteria influence intestinal barrier function and susceptibility to colitis in Nod1-", -; Nod2-, Inflamm. Bowel Dis, pp.2012, 18[DOI]
25. Barrett, J. C., "Genome-wide association study of ulcerative colitis identifies three new susceptibility loci, including the HNF4A region", Nat. Genet, 41, pp.1330~1334 (2009)
26. Silverberg, M. S., "Ulcerative colitis-risk locion chromosomes 1p36 and 12q15 found by genome-wide association study", Nat. Genet, 41, pp.216~220 (2009)
27. Stremmel, W., "Lecithin as a therapeutic agent in ulcerative colitis", Dig. Dis, 31, pp.388~390 (2013)
28. Stremmel, W., "Retarded release phosphatidylcholine benefits patients with chronic active ulcerative colitis", Gut, 54, pp.966~971 (2005)
29. Quigley, E. M., "Small intestinal bacterial overgrowth: roles of antibiotics, prebiotics, and probiotics", Gastroenterology, 130, pp.S78~S90 (2006)
30. Pickard, K. M., "Microbial-gut interactions in health and disease. Immune responses", Best Pract. Res. Clin. Gastroenterol, 18, pp.271~285 (2004)
31. Backhed, F., "Host-bacterial mutualism in the human intestine", Science, 307, pp.1915~1920 (2005)
32. Eckburg, P. B., "Diversity of the human intestinal microbial flora", Science, 308, pp.1635~1638 (2005)
33. Eckburg, P. B., "The role of microbes in Crohn's disease", Clin. Infect. Dis, 44, pp.256~262 (2007)
34. Frank, D. N., "Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases", Proc. Natl. Acad. Sci. U. S. A, 104, pp.13780~13785 (2007)
35. Hiroko Nagao-Kitamoto, "Pathogenic role of the gut microbiota in gastrointestinal diseases", Intestinal research, 14(2), pp.127~138 (2016), 대한장연구학회
36. Khan, K. J., "Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis", Am. J. Gastroenterol, 106, pp.661~673 (2011)
37. Mitsuyama, K., "Antibody markers in the diagnosis of inflammatory bowel disease", World J. Gastroenterol, 22, pp.1304~1310 (2016)
38. Hugot, J. P., "Association of NOD2leucine-rich repeat variants with susceptibility to Crohn's disease", Nature, 411, pp.599~603 (2001)
39. Duerr, R. H., "A genome-wide association study identifies IL23R as an inflammatory bowel disease gene", Science, 314, pp.1461~1463 (2006)
40. Elson, C. O., "Experimental models of inflammatory bowel disease reveal innate, adaptive, and regulatory mechanisms of host dialogue with the microbiota", Immunol. Rev, 206, pp.260~276 (2005)
41. Yang, J. Y., "Enteric viruses ameliorate gut inflammation via Toll-like receptor 3and Toll-like receptor 7-mediated interferon-beta production", Immunity, 44, pp.889~900 (2016)
42. Iliev, I. D., "Interactions between commensal fungi and the C-type lectin receptor Dectin-1influence colitis", Science, 336, pp.1314~1317 (2012)
43. Baumgart, M., "Culture independent analysis of ileal mucosa reveals a selective increase in invasive Escherichia coli of novel phylogeny relative to depletion of Clostridiales in Crohn's disease involving the ileum", ISME. J, 1, pp.403~418 (2007)
44. Martin, H. M., "Enhanced Escherichia coli adherence and invasion in Crohn's disease and colon cancer", Gastroenterology, 127, pp.80~93 (2004)
45. Sasaki, M., "Invasive Escherichia coli are a feature of Crohn's disease", Lab. Invest, 87, pp.1042~1054 (2007)
46. Darfeuille-Michaud, A., "Adherent-invasive Escherichia coli: a putative new E. coli pathotype associated with Crohn's disease", Int. J. Med. Microbiol, 292, pp.185~193 (2002)
47. Martinez-Medina, M., "Molecular diversity of Escherichia coli in the human gut: new ecological evidence supporting the role of adherent-invasive E. coli (AIEC) in Crohn's disease", Inflamm. Bowel Dis, 15, pp.872~882 (2009)
48. Manichanh, C., "Reduced diversity of faecal microbiota in Crohn's disease revealed by a metagenomic approach", Gut, 55, pp.205~211 (2006)
49. Darfeuille-Michaud, A., "High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn's disease", Gastroenterology, 127, pp.412~421 (2004)
50. Atarashi, K., "Induction of colonic regulatory T cells by indigenous Clostridium species", Science, 331, pp.337~341 (2011)
51. Honda, K., "The microbiome in infectious disease and inflammation", Annu. Rev. Immunol, 30, pp.759~795 (2012)
52. Feuerer, M., "Genomic definition of multiple ex vivo regulatory T cell subphenotypes", Proc. Natl. Acad. Sci. U. S. A, 107, pp.5919~5924 (2010)
53. Cong, Y., "A dominant, coordinated T regulatory cell-IgA response to the intestinal microbiota", Proc. Natl. Acad. Sci. U. S. A, 106, pp.19256~19261 (2009)
54. Sokol, H., "Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients", Proc. Natl. Acad. Sci. U. S. A, 105, pp.16731~16736 (2008)
55. Willing, B., "Twin studies reveal specific imbalances in the mucosa-associated microbiota of patients with ileal Crohn's disease", Inflamm. Bowel Dis, 15, pp.653~660 (2009)
56. Moayyedi, P., "Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial", Gastroenterology, 149, pp.102~109 (2015)
57. Rossen, N. G., "Findings from a randomized controlled trial of fecal transplantation for patients with ulcerative colitis", Gastroenterology, 149, pp.110~118 (2015)
58. Colman, R. J., "Fecal microbiota transplantation as therapy for inflammatory bowel disease:a systematic review and meta-analysis", J. Crohns. Colitis, 8, pp.1569~1581 (2014)
59. Rachmilewitz, D., "Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis", Gastroenterology, 126, pp.520~528 (2004)
60. Shen, J., "Effect of probiotics on inducing remission and maintaining therapy in ulcerative colitis, Crohn's disease, and pouchitis: meta-analysis of randomized controlled trials", Inflamm. Bowel Dis, 20, pp.21~35 (2014)
61. Kawai, T., "Toll-like receptors and their crosstalk with other innate receptors in infection and immunity", Immunity, 34, pp.637~650 (2011)
62. Akira, S., "Pathogen recognition and innate immunity", Cell, 124, pp.783~801 (2006)
63. Podolsky, D. K., "Colitis-associated variant of TLR2 causes impaired mucosal repair because of TFF3 deficiency", Gastroenterology, 137, pp.209~220 (2009)
64. Cho, J. H., "Recent insights into the genetics of inflammatory bowel disease", Gastroenterology, 140, pp.1704~1712 (2011)
65. Jostins, L., "Hostmicrobe interactions have shaped the genetic architecture of inflammatory bowel disease", Nature, 491, pp.119~124 (2012)
66. Steinbach, E. C., "The role of macrophages and dendritic cells in the initiation of inflammation in IBD", Inflamm. Bowel Dis, 20, pp.166~175 (2014)
67. Hampe, J., "A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1", Nat. Genet, 39, pp.207~211 (2007)
68. Rioux, J. D., "Genome-wide association study identifies new susceptibility loci for Crohn disease and implicates autophagy in disease pathogenesis", Nat. Genet, 39, pp.596~604 (2007)
69. Libioulle, C., "Novel Crohn disease locus identified by genome-wide association maps to a gene desert on 5p13.1 and modulates expression of PTGER4", PLoS Genet, 3, pp.e58~ (2007)
70. Parkes, M., "Sequence variants in the autophagy gene IRGM and multiple other replicating loci contribute to Crohn's disease susceptibility", Nat. Genet, 39, pp.830~832 (2007)
71. Moon, C. M., "Associations between genetic variants in the IRGM gene and inflammatory bowel diseases in the Korean population", Inflamm. Bowel Dis, 19, pp.106~114 (2013)
72. Uhlig, H. H., "Differential activity of IL-12 and IL-23 in mucosal and systemic innate immune pathology", Immunity, 25, pp.309~318 (2006)
73. Vong, L., "A pro-resolution mediator, prostaglandin D(2), is specifically up-regulated in individuals in long-term remission from ulcerative colitis", Proc. Natl. Acad. Sci. U. S. A, 107, pp.12023~12027 (2010)
74. Friedman, D. J., "From the Cover: CD39 deletion exacerbates experimental murine colitis and human polymorphisms increase susceptibility to inflammatory bowel disease", Proc. Natl. Acad. Sci. U. S. A, 106, pp.16788~16793 (2009)
75. Dieckgraefe, B. K., "Growth factors as treatment options for intestinal inflammation", Ann. N. Y. Acad. Sci, 1072, pp.300~306 (2006)
76. Weaver, C. T., "The Th17 pathway and inflammatory diseases of the intestines, lungs, and skin", Annu. Rev. Pathol, 8, pp.477~512 (2013)
77. Neurath, M. F., "Cytokines in inflammatory bowel disease", Nat. Rev. Immunol, 14, pp.329~342 (2014)
78. Truelove, S., "Cortisone in ulcerative colitis; preliminary report on a therapeutic trial", Gastroenterologia, 81, pp.86~90 (1954)
79. Flammer, J. R., "Minireview:Glucocorticoids in autoimmunity: unexpected targets and mechanisms", Mol. Endocrinol, 25, pp.1075~1086 (2011)
80. 김덕환, "Clinical Outcomes and Predictive Factors for Response after the First Course of Corticosteroid Therapy in Patients with Crohn’s Disease", Gut and Liver, 7(1), pp.58~65 (2013), 거트앤리버 발행위원회
81. Kornbluth, A., "Cyclosporin for severe ulcerative colitis: a user's guide", Am. J. Gastroenterol, 92, pp.1424~1428 (1997)
82. Feagan, B. G., "A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease", N. Engl. J. Med, 342, pp.1627~1632 (2000)
83. Feagan, B. G., "Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators", N. Engl. J. Med, 332, pp.292~297 (1995)
84. Lennard, L., "The clinical pharmacology of 6-mercaptopurine", Eur. J. Clin. Pharmacol, 43, pp.329~339 (1992)
85. Tiede, I., "CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J. Clin", Invest, 111, pp.1133~1145 (2003)
86. M E Wildenberg, "The ATG16L1 risk allele associated with Crohn’s disease results in a Rac1-dependent defect in dendritic cell migration that is corrected by thiopurines", Mucosal Immunology, 10(2), pp.352~360 (2016), Springer Nature[DOI]
87. Oancea, I., "Colonic microbiota can promote rapid local improvement of murine colitis by thioguanine independently of T lymphocytes and host metabolism", Gut, 66, pp.59~69 (2017)
88. Dewit, O., "Limitations of extensive TPMT genotyping in the management of azathioprine-induced myelosuppression in IBD patients", Clin. Biochem, 44, pp.1062~1066 (2011)
89. Yang, S. K., "A common missense variant in NUDT15 confers susceptibility to thiopurine-induced leukopenia", Nat. Genet, 46, pp.1017~1020 (2014)
90. Han Sang Kim, "A coding variant in FTO confers susceptibility to thiopurine-induced leukopenia in East Asian patients with IBD", Gut, 66(11), pp.1926~1935 (2016), BMJ[DOI]
91. Melmed, G. Y., "Future biologic targets for IBD: potentials and pitfalls", Nat. Rev. Gastroenterol. Hepatol, 7, pp.110~117 (2010)
92. Present, D. H., "Infliximab for the treatment of fistulas in patients with Crohn's disease", N. Engl. J. Med, 340, pp.1398~1405 (1999)
93. Kontoyiannis, D., "Impaired on", off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements : implications for joint and gut-associated immunopathologies, 1999, pp.10, 387~398
94. Kojouharoff, G., "Neutralization of tumour necrosis factor (TNF) but not of IL-1 reduces inflammation in chronic dextran sulphate sodium-induced colitis in mice", Clin. Exp. Immunol, 107, pp.353~358 (1997)
95. Wajant, H., "Tumor necrosis factor signaling", Cell Death Differ, 10, pp.45~65 (2003)
96. Neurath, M. F., "New targets for mucosal healing and therapy in inflammatory bowel diseases", Mucosal Immunol, 7, pp.6~19 (2014)
97. Holtmann, M. H., "Tumor necrosis factor-receptor 2 is up-regulated on lamina propria T cells in Crohn's disease and promotes experimental colitis in vivo", Eur. J. Immunol, 32, pp.3142~3151 (2002)
98. Perrier, C., "Neutralization of membrane TNF, but not soluble TNF, is crucial for the treatment of experimental colitis", Inflamm. Bowel Dis, 19, pp.246~253 (2013)
99. Colombel, J. F., "Infliximab, azathioprine, or combination therapy for Crohn's disease", N. Engl. J. Med, 362, pp.1383~1395 (2010)
100. Colombel, J. F., "Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease : the CHARM trial", Gastroenterology, 132, pp.52~65 (2007)
101. Hanauer, S. B., "Human anti-tumor necrosis factor monoclonal antibody(adalimumab)in Crohn's disease : the CLASSIC-I trial", Gastroenterology, 130, pp.323~333 (2006)
102. Hanauer, S. B., "Maintenance infliximab for Crohn's disease : the ACCENT I randomised trial", Lancet, 359, pp.1541~1549 (2002)
103. Colombel, J. F., "Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis", Gastroenterology, 141, pp.1194~1201 (2011)
104. Evans, A. T., "A review and expert opinion of the use of certolizumab for Crohn's disease", Expert Opin. Biol. Ther, 12, pp.363~370 (2012)
105. Lowenberg, M., "Golimumab for the treatment of ulcerative colitis", Clin. Exp. Gastroenterol, 7, pp.53~59 (2014)
106. Van den Brande, J. M., "Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease", Gastroenterology, 124, pp.1774~1785 (2003)
107. Sandborn, W. J., "Etanercept for active Crohn's disease : a randomized, double-blind, placebo-controlled trial", Gastroenterology, 121, pp.1088~1094 (2001)
108. Zeissig, S., "Downregulation of epithelial apoptosis and barrier repair in active Crohn's disease by tumour necrosis factor alpha antibody treatment", Gut, 53, pp.1295~1302 (2004)
109. Vos, A. C., "Anti-tumor necrosis factor-alpha antibodies induce regulatory macrophages in an Fc region-dependent manner", Gastroenterology, 140, pp.221~230 (2011)
110. Vos, A. C., "Regulatory macrophages induced by infliximab are involved in healing in vivo and in vitro", Inflamm. Bowel. Dis, 18, pp.401~408 (2012)
111. Bhol, K. C., "AVX-470:a novel oral anti-TNF antibody with therapeutic potential in inflammatory bowel disease", Inflamm. Bowel Dis, 19, pp.2273~2281 (2013)
112. Vandenbroucke, K., "Orally administered L. lactis secreting an anti-TNF Nanobody demonstrate efficacy in chronic colitis", Mucosal Immunol, 3, pp.49~56 (2010)
113. Assier, E., "Modulation of anti-tumor necrosis factor alpha (TNF-alpha) antibody secretion in mice immunized with TNF-alpha kinoid", Clin. Vaccine Immunol, 19, pp.699~703 (2012)
114. Monteleone, I., "Th17-related cytokines: new players in the control of chronic intestinal inflammation", BMC Med, 9, pp.122~ (2011)
115. Zenewicz, L. A., "CD4 T-cell differentiation and inflammatory bowel disease", Trends Mol. Med, 15, pp.199~207 (2009)
116. Caruso, R., "A functional role for interleukin-21 in promoting the synthesis of the T-cell chemoattractant, MIP-3alpha, by gut epithelial cells", Gastroenterology, 132, pp.166~175 (2007)
117. Huang, Y., "Inflammatory bowel disease related innate immunity and adaptive immunity", Am. J. Transl. Res, 8, pp.2490~2497 (2016)
118. Reinisch, W., "Fontolizumab in moderate to severe Crohn's disease: a phase 2, randomized, double-blind, placebocontrolled, multiple-dose study", Inflamm. Bowel Dis, 16, pp.233~242 (2010)
119. Hueber, W., "Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial", Gut, 61, pp.1693~1700 (2012)
120. Pickert, G, "STAT3 links IL-22 signaling in intestinal epithelial cells to mucosal wound healing", J. Exp. Med, 206, pp.1465~1472 (2009)
121. Ueno, A, "Th17plasticity and its changes associated with inflammatory bowel disease", World J. Gastroenterol, 21, pp.12283~12295 (2015)
122. Shih, D. Q., "Recent advances in IBD pathogenesis: genetics and immunobiology", Curr. Gastroenterol. Rep, 10, pp.568~575 (2008)
123. Feagan, B. G, "Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease", N. Engl. J. Med, 375, pp.1946~1960 (2016)
124. Mannon, P. J, "Anti-interleukin-12 antibody for active Crohn's disease", N. Engl. J. Med, 351, pp.2069~2079 (2004)
125. Sands, B. E., "Randomized, double-blind, placebo-controlled trial of the oral interleukin-12", 23 inhibitor apilimod mesylate for treatment of active Crohn's disease, 2010, pp.16, 1209~1218
126. Davidson, N. J, "T helper cell 1-type CD4+ T cells, but not B cells, mediate colitis in interleukin 10-deficient mice", J. Exp. Med, 184, pp.241~251 (1996)
127. Erdman, S. E, "CD4(+)CD25(+) regulatory lymphocytes require interleukin 10 to interrupt colon carcinogenesis in mice", Cancer Res, 63, pp.6042~6050 (2003)
128. Steidler, L, "Treatment of murine colitis by Lactococcus lactis secreting interleukin-10", Science, 289, pp.1352~1355 (2000)
129. Danese, S, "JAK inhibition using tofacitinib for inflammatory bowel disease treatment: a hub for multiple inflammatory cytokines", Am. J. Physiol. Gastrointest. Liver Physiol, 310, pp.G155~G162 (2016)
130. Ghoreschi, K, "Janus kinases in immune cell signaling", Immunol. Rev, 228, pp.273~287 (2009)
131. Sandborn, W. J, "Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis", N. Engl. J. Med, 367, pp.616~624 (2012)
132. Sandborn, W. J, "A phase 2 study of tofacitinib, an oral Janus kinase inhibitor, in patients with Crohn's disease", Clin. Gastroenterol. Hepatol, 12, pp.1485~1493 (2014)
133. Monteleone, G, "TGF-beta1 and Smad7 in the regulation of IBD", Mucosal Immunol, 1(Suppl 1), pp.S50~S53 (2008)
134. Monteleone, G, "Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn's disease", N. Engl. J. Med, 372, pp.1104~1113 (2015)
135. Sandborn, W. J, "Abatacept for Crohn's disease and ulcerative colitis", Gastroenterology, 143, pp.62~69 (2012)
136. Sandborn, W. J, "Natalizumab induction and maintenance therapy for Crohn's disease", N. Engl. J. Med, 353, pp.1912~1925 (2005)
137. Maas, R. P, "Drug-associated progressive multifocal leukoencephalopathy:a clinical, radiological, and cerebrospinal fluid analysis of 326cases", J. Neurol, 263, pp.2004~2021 (2016)
138. Sandborn, W. J, "Vedolizumab as induction and maintenance therapy for Crohn's disease", N. Engl. J. Med, 369, pp.711~721 (2013)
139. Feagan, B. G, "Vedolizumab as induction and maintenance therapy for ulcerative colitis", N. Engl. J. Med, 369, pp.699~710 (2013)
140. Vermeire, S, "Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial", Lancet, 384, pp.309~318 (2014)
141. Sandborn, W, "825 Anti-MAdCAM-1 antibody (PF-00547659) for active refractory Crohn's disease: Results of the OPERA study", Gastroenterology, 148, pp.S-162~ (2015)
142. Reinisch, W., "901a A randomized, multicenter double-blind, placebo-controlled study of the safety and efficacy of anti-MAdCAM antibody PF-00547659 (PF) in patients with moderate to severe ulcerative colitis: Results of the TURANDOT study", Gastroenterology, 148, pp.S-1193~ (2015)

관련 논문AI추천